Brun-Buisson C: The epidemiology of the systemic inflammatory response. Intensive Care Med 2000,26(Suppl 1):S64-S74.
Article
PubMed
Google Scholar
Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, EPIC II Group of Investigators: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302: 2323-2329. 10.1001/jama.2009.1754
Article
CAS
PubMed
Google Scholar
Póvoa P: Serum markers in community-acquired pneumonia and ventilator-associated pneumonia. Curr Opin Infect Dis 2008, 21: 157-162. 10.1097/QCO.0b013e3282f47c32
Article
PubMed
Google Scholar
Craig WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003, 17: 479-501. 10.1016/S0891-5520(03)00065-5
Article
PubMed
Google Scholar
Estes L: Review of pharmacokinetics and pharmacodynamics of antimicrobial agents. Mayo Clin Proc 1998, 73: 1114-1122. 10.4065/73.11.1114
Article
CAS
PubMed
Google Scholar
Pea F, Viale P, Furlanut M: Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005, 44: 1009-1034. 10.2165/00003088-200544100-00002
Article
CAS
PubMed
Google Scholar
Mehrotra R, De Gaudio R, Palazzo M: Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004, 30: 2145-2156. 10.1007/s00134-004-2428-9
Article
PubMed
Google Scholar
Fuster-Lluch O, Gerónimo-Pardo M, Peyró-García R, Lizán-García M: Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 2008, 36: 674-680.
CAS
PubMed
Google Scholar
Baptista JP, Udy AA, Sousa E, Pimentel J, Wang L, Roberts JA, Lipman J: A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 2011, 15: R139. 10.1186/cc10262
Article
PubMed Central
PubMed
Google Scholar
Verdant C, De Backer D: How monitoring of the microcirculation may help us at the bedside. Curr Opin Crit Care 2005, 11: 240-244. 10.1097/01.ccx.0000158849.94225.11
Article
PubMed
Google Scholar
Levitt DG: The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol 2003, 3: 3.
Article
PubMed Central
PubMed
Google Scholar
Triginer C, Izquierdo I, Fernandez R, Rello J, Torrent J, Benito S, Net A: Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990, 16: 303-306. 10.1007/BF01706354
Article
CAS
PubMed
Google Scholar
Hansen M, Christrup LL, Jarløv JO, Kampmann JP, Bonde J: Gentamicin dosing in critically ill patients. Acta Anaesthesiol Scand 2001, 45: 734-740. 10.1034/j.1399-6576.2001.045006734.x
Article
CAS
PubMed
Google Scholar
Roberts JA, Lipman J: Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006, 45: 755-773. 10.2165/00003088-200645080-00001
Article
CAS
PubMed
Google Scholar
Drusano GL: Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 2007,45(Suppl 1):S89-S95.
Article
CAS
PubMed
Google Scholar
Mouton JW: Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin North Am 2003, 17: 579-598. 10.1016/S0891-5520(03)00062-X
Article
PubMed
Google Scholar
Choi G, Gomersall CD, Tian Q, Joynt GM, Li AM, Lipman J: Principles of antibacterial dosing in continuous renal replacement therapy. Blood Purif 2010, 30: 195-212. 10.1159/000321488
Article
CAS
PubMed
Google Scholar
Shah PM: Parenteral carbapenems. Clin Microbiol Infect 2008, 14: 175-180. 10.1111/j.1469-0691.2007.01868.x
Article
CAS
PubMed
Google Scholar
de Stoppelaar F, Stolk L, van Tiel F, Beysens A, van der Geest S, de Leeuw P: Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia. J Antimicrob Chemother 2000, 46: 150-151. 10.1093/jac/46.1.150
Article
CAS
PubMed
Google Scholar
Jaruratanasirikul S, Sriwiriyajan S, Punyo J: Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005, 49: 1337-1339. 10.1128/AAC.49.4.1337-1339.2005
Article
PubMed Central
CAS
PubMed
Google Scholar
Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA: Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 2002, 19: 105-110. 10.1016/S0924-8579(01)00474-5
Article
CAS
PubMed
Google Scholar
Lovering AM, Vickery CJ, Watkin DS, Leaper D, McMullin CM, White LO, Reeves DS, MacGowan AP: The pharmacokinetics of meropenem in surgical patients with moderate or severe infections. J Antimicrob Chemother 1995, 36: 165-172. 10.1093/jac/36.1.165
Article
CAS
PubMed
Google Scholar
Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Witebolle X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F: Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14: R126. 10.1186/cc9091
Article
PubMed Central
PubMed
Google Scholar
Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64: 142-150. 10.1093/jac/dkp139
Article
CAS
PubMed
Google Scholar
Karjagin J, Lefeuvre S, Oselin K, Kipper K, Marchand S, Tikkerberi A, Starkopf J, Couet W, Sawchuk RJ: Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther 2008, 83: 452-459. 10.1038/sj.clpt.6100312
Article
CAS
PubMed
Google Scholar
Rhomberg PR, Jones RN: Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007, 57: 207-215. 10.1016/j.diagmicrobio.2006.07.009
Article
CAS
PubMed
Google Scholar
Thalhammer F, Traunmüller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H: Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999, 43: 523-527. 10.1093/jac/43.4.523
Article
CAS
PubMed
Google Scholar
Belzberg H, Zhu J, Cornwell EE, Murray JA, Sava J, Salim A, Velmahos GC, Gill MA: Imipenem levels are not predictable in the critically ill patient. J Trauma 2004, 56: 111-117. 10.1097/01.TA.0000056164.26493.28
Article
PubMed
Google Scholar
Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR: Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005, 44: 539-549. 10.2165/00003088-200544050-00007
Article
CAS
PubMed
Google Scholar
Jaruratanasirikul S, Sudsai T: Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion. J Antimicrob Chemother 2009, 63: 560-563. 10.1093/jac/dkn543
Article
CAS
PubMed
Google Scholar
Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sörgel F: Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007, 51: 3304-3310. 10.1128/AAC.01318-06
Article
PubMed Central
CAS
PubMed
Google Scholar
Tegeder I, Schmidtko A, Bräutigam L, Kirschbaum A, Geisslinger G, Lötsch J: Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002, 71: 325-333. 10.1067/mcp.2002.122526
Article
CAS
PubMed
Google Scholar
Dahyot C, Marchand S, Bodin M, Debeane B, Mimoz O, Couet W: Application of basic pharmacokinetic concepts to analysis of microdialysis data: illustration with imipenem muscle distribution. Clin Pharmacokinet 2008, 47: 181-189. 10.2165/00003088-200847030-00004
Article
CAS
PubMed
Google Scholar
McKindley DS, Boucher BA, Hess MM, Croce MA, Fabian TC: Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy 1996, 16: 924-931.
CAS
PubMed
Google Scholar
Muller-Serieys C, Bergogne-Berezin E, Rowan C, Dombret MC: Imipenem penetration into bronchial secretions. J Antimicrob Chemother 1987, 20: 618-619. 10.1093/jac/20.4.618
Article
CAS
PubMed
Google Scholar
Shikuma LR, Ackerman BH, Weaver RH, Solem LD, Strate RG, Cerra FB, Zaske DE: Effects of treatment and the metabolic response to injury on drug clearance: a prospective study with piperacillin. Crit Care Med 1990, 18: 37-41.
Article
CAS
PubMed
Google Scholar
Conil JM, Georges B, Mimoz O, Dieye E, Ruiz S, Cougot P, Samii K, Houin G, Saivin S: Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Intensive Care Med 2006, 32: 2063-2066. 10.1007/s00134-006-0421-1
Article
CAS
PubMed
Google Scholar
Bourget P, Lesne-Hulin A, Le Reveillé R, Le Bever H, Carsin H: Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 1996, 40: 139-145.
PubMed Central
CAS
PubMed
Google Scholar
Langgartner J, Lehn N, Glück T, Herzig H, Kees F: Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion. Chemotherapy 2007, 53: 370-377. 10.1159/000107725
Article
CAS
PubMed
Google Scholar
Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, Fazeli MR: Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006, 28: 122-127. 10.1016/j.ijantimicag.2006.02.020
Article
CAS
PubMed
Google Scholar
Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmelé T, Chassard D, Saux MC, Allaouchiche B: Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004, 30: 976-979. 10.1007/s00134-004-2222-8
Article
PubMed
Google Scholar
Jehl F, Muller-Serieys C, de Larminat V, Monteil H, Bergogne-Berezin E: Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients. Antimicrob Agents Chemother 1994, 38: 2780-2784.
Article
PubMed Central
CAS
PubMed
Google Scholar
Boselli E, Breilh D, Rimmelé T, Guillaume C, Xuereb F, Saux MC, Bouvet L, Chassard D, Allaouchiche B: Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med 2008, 36: 1500-1506. 10.1097/CCM.0b013e318170ba21
Article
CAS
PubMed
Google Scholar
Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, Eichler HG, Müller M: Impaired target site penetration of β-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001, 29: 385-391. 10.1097/00003246-200102000-00030
Article
CAS
PubMed
Google Scholar
Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Piperacillin penetration into tissue of critically ill patients with sepsis: bolus versus continuous administration? Crit Care Med 2009, 37: 926-933. 10.1097/CCM.0b013e3181968e44
Article
PubMed
Google Scholar
Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J: First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2009, 35: 156-163.
Article
PubMed
Google Scholar
Jacolot A, Incagnoli P, Edouard AR, Tod M, Petitjean O, Samii K, Mimoz O: Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome. Intensive Care Med 1999, 25: 486-491. 10.1007/s001340050885
Article
CAS
PubMed
Google Scholar
Lipman J, Wallis SC, Rickard CM, Fraenkel D: Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001, 27: 363-370. 10.1007/s001340000741
Article
CAS
PubMed
Google Scholar
Lipman J, Wallis SC, Boots RJ: Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 2003, 97: 1149-1154.
Article
CAS
PubMed
Google Scholar
Roos JF, Lipman J, Kirkpatrick CM: Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med 2007, 33: 781-788. 10.1007/s00134-007-0573-7
Article
CAS
PubMed
Google Scholar
Sauermann R, Delle-Karth G, Marsik C, Steiner I, Zeitlinger M, Mayer-Helm BX, Georgopoulos A, Müller M, Joukhadar C: Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob Agents Chemother 2005, 49: 650-655. 10.1128/AAC.49.2.650-655.2005
Article
PubMed Central
CAS
PubMed
Google Scholar
Joukhadar C, Klein N, Mayer BX, Kreischitz N, Delle-Karth G, Palkovits P, Heinz G, Müller M: Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med 2002, 30: 1478-1482. 10.1097/00003246-200207000-00013
Article
CAS
PubMed
Google Scholar
Kieft H, Hoepelman AI, Knupp CA, van Dijk A, Branger JM, Struyvenberg A, Verhoef J: Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother 1993,32(Suppl B):117-122.
Article
PubMed
Google Scholar
Conil JM, Georges B, Lavit M, Seguin T, Tack I, Samii K, Chabanon G, Houin G, Saivin S: Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance. Int J Clin Pharmacol Ther 2007, 45: 529-538.
Article
CAS
PubMed
Google Scholar
Chapuis TM, Giannoni E, Majcherczyk PA, Chioléro R, Schaller MD, Berger MM, Bolay S, Décosterd LA, Bugnon D, Moreillon P: Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010, 14: R51. 10.1186/cc8941
Article
PubMed Central
PubMed
Google Scholar
Lipman J, Wallis SC, Rickard C: Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999, 43: 2559-2561.
PubMed Central
CAS
PubMed
Google Scholar
Bonapace CR, White RL, Friedrich LV, Norcross ED, Bosso JA: Pharmacokinetics of cefepime in patients with thermal burn injury. Antimicrob Agents Chemother 1999, 43: 2848-2854.
PubMed Central
CAS
PubMed
Google Scholar
Georges B, Conil JM, Seguin T, Dieye E, Cougot P, Decun JF, Lavit M, Samii K, Houin G, Saivin S: Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables. Int J Clin Pharmacol Ther 2008, 46: 157-164.
Article
CAS
PubMed
Google Scholar
Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, Nicolau DP: Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009, 53: 1476-1481. 10.1128/AAC.01141-08
Article
PubMed Central
CAS
PubMed
Google Scholar
Roos JF, Bulitta J, Lipman J, Kirkpatrick CM: Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006, 58: 987-993. 10.1093/jac/dkl349
Article
CAS
PubMed
Google Scholar
Sampol E, Jacquet A, Viggiano M, Bernini V, Manelli JC, Lacarelle B, Durand A: Plasma, urine and skin pharmacokinetics of cefepime in burns patients. J Antimicrob Chemother 2000, 46: 315-317. 10.1093/jac/46.2.315
Article
CAS
PubMed
Google Scholar
Klekner A, Bágyi K, Bognár L, Gáspár A, Andrási M, Szabó J: Effectiveness of cephalosporins in the sputum of patients with nosocomial bronchopneumonia. J Clin Microbiol 2006, 44: 3418-3421. 10.1128/JCM.00893-06
Article
PubMed Central
CAS
PubMed
Google Scholar
Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B: Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 2003, 31: 2102-2106. 10.1097/01.CCM.0000069734.38738.C8
Article
CAS
PubMed
Google Scholar
Rondanelli R, Dionigi RV, Regazzi MB, Maurelli M, Calvi M, Mapelli A: Ceftazidime in the treatment of Pseudomonas infections in intensive-care patients. Int J Clin Pharmacol Ther Toxicol 1986, 24: 457-459.
CAS
PubMed
Google Scholar
Young RJ, Lipman J, Gin T, Gomersall CD, Joynt GM, Oh TE: Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 1997, 40: 269-273. 10.1093/jac/40.2.269
Article
CAS
PubMed
Google Scholar
Gómez CM, Cordingly JJ, Palazzo MG: Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999, 43: 1798-1802.
PubMed Central
PubMed
Google Scholar
Benko AS, Cappelletty DM, Kruse JA, Rybak MJ: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996, 40: 691-695.
PubMed Central
CAS
PubMed
Google Scholar
Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ: Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999, 43: 309-311. 10.1093/jac/43.2.309
Article
CAS
PubMed
Google Scholar
Boselli E, Breilh D, Rimmelé T, Poupelin JC, Saux MC, Chassard D, Allaouchiche B: Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004, 30: 989-991. 10.1007/s00134-004-2171-2
Article
PubMed
Google Scholar
Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA: Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000, 179: 436-440. 10.1016/S0002-9610(00)00388-3
Article
CAS
PubMed
Google Scholar
Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, Chaowagul W, White NJ: Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000, 50: 184-191. 10.1111/j.1365-2125.2000.00179.x
Article
PubMed Central
CAS
PubMed
Google Scholar
Aubert G, Carricajo A, Coudrot M, Guyomarc'h S, Auboyer C, Zeni F: Prospective determination of serum ceftazidime concentrations in intensive care units. Ther Drug Monit 2010, 32: 517-519. 10.1097/FTD.0b013e3181e60ca6
Article
CAS
PubMed
Google Scholar
Georges B, Conil JM, Seguin T, Ruiz S, Minville V, Cougot P, Decun JF, Gonzalez H, Houin G, Fourcade O, Saivin S: Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission. Antimicrob Agents Chemother 2009, 53: 4483-4489. 10.1128/AAC.00430-09
Article
PubMed Central
CAS
PubMed
Google Scholar
Buijk SL, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA: Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002, 49: 121-128. 10.1093/jac/49.1.121
Article
CAS
PubMed
Google Scholar
Mouton JW, Punt N, Vinks AA: A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 2005, 27: 762-772. 10.1016/j.clinthera.2005.06.013
Article
CAS
PubMed
Google Scholar
Langer M, Cantoni P, Bellosta C, Boccazzi A: Penetration of ceftazidime into bronchial secretions in critically ill patients. J Antimicrob Chemother 1991, 28: 925-932. 10.1093/jac/28.6.925
Article
CAS
PubMed
Google Scholar
Bressolle F, de La Coussaye JE, Ayoub R, Fabre D, Gomeni R, Saissi G, Eledjam JJ, Galtier M: Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability. Antimicrob Agents Chemother 1992, 36: 1404-1411.
Article
PubMed Central
CAS
PubMed
Google Scholar
Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK, Gaynes RP, Tenover FC, Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Hospitals: Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE Phase 2. Clin Infect Dis 1999, 29: 245-252. 10.1086/520193
Article
CAS
PubMed
Google Scholar
Chatellier D, Jourdain M, Mangalaboyi J, Ader F, Chopin C, Derambure P, Fourrier F: Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med 2002, 28: 214-217. 10.1007/s00134-001-1170-9
Article
CAS
PubMed
Google Scholar
Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J: Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010, 36: 332-339. 10.1016/j.ijantimicag.2010.06.008
Article
CAS
PubMed
Google Scholar
Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL: Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010, 25: 69-77. 10.1016/j.jcrc.2009.02.014
Article
CAS
PubMed
Google Scholar
McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31: 345-351. 10.1016/j.ijantimicag.2007.12.009
Article
CAS
PubMed
Google Scholar
Gentry LO, Rodriguez-Gomez G: Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. Antimicrob Agents Chemother 1991, 35: 2371-2374.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA: Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005, 39: 32-38.
Article
CAS
PubMed
Google Scholar
Mouton JW, Vinks AA, Punt NC: Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997, 41: 733-738.
PubMed Central
CAS
PubMed
Google Scholar
Nicolau DP: Pharmacodynamic optimization of β-lactams in the patient care setting. Crit Care 2008, 12: S2.
Article
PubMed Central
PubMed
Google Scholar
Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME: Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005, 5: 581-589. 10.1016/S1473-3099(05)70218-8
Article
CAS
PubMed
Google Scholar
Roberts JA, Webb S, Paterson D, Ho KM, Lipman J: A systematic review on clinical benefits of continuous administration of β-lactam antibiotics. Crit Care Med 2009, 37: 2071-2078. 10.1097/CCM.0b013e3181a0054d
Article
CAS
PubMed
Google Scholar
Ljungberg B, Nilsson-Ehle I: Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob Agents Chemother 1992, 36: 1437-1440.
Article
PubMed Central
CAS
PubMed
Google Scholar
Drusano GL, Standiford HC, Bustamante C, Forrest A, Rivera G, Leslie J, Tatem B, Delaportas D, MacGregor RR, Schimpff SC: Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother 1984, 26: 715-721.
Article
PubMed Central
CAS
PubMed
Google Scholar
Paradis D, Vallée F, Allard S, Bisson C, Daviau N, Drapeau C, Auger F, LeBel M: Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother 1992, 36: 2085-2092.
Article
PubMed Central
CAS
PubMed
Google Scholar
Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J, Martin RR: Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 1992, 36: 552-557.
Article
PubMed Central
CAS
PubMed
Google Scholar
Dawson-Saunders B, Trapp RG: Basic & Clinical Biostatistics. 2nd edition. Chicago: Appleton & Lange; 1994.
Google Scholar